AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10806282 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (20 mg)
Number of subjects: 209
Study 10806282 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 209
Study 10806282 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 209
Study 10163928 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet spacer device (MDI with Jet spacer)
Number of subjects: 36
Study 10163928 — intervention group
Group type: COMPARATOR
Intervention: Standard actuator (MDI with standard actuator)
Number of subjects: 36
Study 8274805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-activity group (physically inactive subjects)
Number of subjects: 76
Study 8274805 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with disk protrusion
Number of subjects: 76
Study 8274805 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 76
Study 8274805 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 76
Study 3020700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/doxorubicin/etoposide (CAE)
Number of subjects: 0
Study 3020700 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/doxorubicin/vincristine (CAV)
Number of subjects: 0
Study 29894467 — intervention group
Group type: EXPERIMENTAL
Intervention: Masseter muscle injection with type A botulinum toxin
Number of subjects: 8
Study 29894467 — intervention group
Group type: COMPARATOR
Intervention: No masseter muscle injection with type A botulinum toxin (Control)
Number of subjects: 8
Study 27178854 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz rTMS to S2
Number of subjects: 57
Study 27178854 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 57
Study 25922111 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week maximal isokinetic training of the stronger ankle dorsiflexors at 90°/s
Number of subjects: 30
Study 25922111 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 30
Study 23579106 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NMES
Number of subjects: 31
Study 23579106 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive NMES
Number of subjects: 31
Study 23579106 — intervention group
Group type: COMPARATOR
Intervention: Control (sham stimulation)
Number of subjects: 31
Study 21624491 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1236 75 mg, twice daily for 6 weeks
Number of subjects: 74
Study 21624491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 17487212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (20% of energy), high-fiber (18 g per 1000 kcals of energy intake), high-fruit and -vegetable (5-8 servings per day) dietary intervention
Number of subjects: 750
Study 17487212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 750
Study 17487212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable dietary intervention (in lean subjects only)
Number of subjects: 750
Study 17487212 — intervention group
Group type: COMPARATOR
Intervention: Control group (in lean subjects only)
Number of subjects: 750
Study 17487212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable dietary intervention
Number of subjects: 750
Study 16636357 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR+AED
Number of subjects: 1260
Study 16636357 — intervention group
Group type: COMPARATOR
Intervention: CPR
Number of subjects: 1260
Study 12955427 — intervention group
Group type: COMPARATOR
Intervention: 1-month clopidogrel therapy (75 mg p.o. for 1 month)
Number of subjects: 278
Study 12955427 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month clopidogrel therapy (75 mg p.o. for 6 months)
Number of subjects: 278
Study 11149434 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulatory occlusion by tourniquet
Number of subjects: 18
Study 11149434 — intervention group
Group type: EXPERIMENTAL
Intervention: Exsanguination
Number of subjects: 18
Study 9410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with wheezing
Number of subjects: 53
Study 9410298 — intervention group
Group type: COMPARATOR
Intervention: Randomized school children
Number of subjects: 53
Study 9410298 — intervention group
Group type: COMPARATOR
Intervention: Asthmatic children
Number of subjects: 53
Study 1583761 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) CPR
Number of subjects: 10
Study 1583761 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 10
Study 1583761 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Thumper CPR
Number of subjects: 10
Study 3896657 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg) once daily
Number of subjects: 8
Study 3896657 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg) once daily
Number of subjects: 8
Study 3896657 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg) twice daily at 08.00 and 20.00 hours
Number of subjects: 8
Study 3896657 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg) twice daily at 08.00 and 12.00 hours or 08.00 and 20.00 hours
Number of subjects: 8
Study 30967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) intervention
Number of subjects: 202
Study 30967321 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 202
Study 30555463 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel vaccine approaches for malaria
Number of subjects: 0
Study 27038798 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for primary care physicians
Number of subjects: 0
Study 27038798 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training plus access to an evidence-based point-of-care tool
Number of subjects: 0
Study 27038798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 25424793 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 339
Study 25424793 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 339
Study 25424793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PPV23 and PCV7
Number of subjects: 339
Study 22289113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan ODT 5mg (for <40kg group)
Number of subjects: 0
Study 22289113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan ODT 10mg (for ≥40kg group)
Number of subjects: 0
Study 22289113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for <40kg group)
Number of subjects: 0
Study 22289113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for ≥40kg group)
Number of subjects: 0
Study 22289113 — intervention group
Group type: COMPARATOR
Intervention: Comparison with historical adult data
Number of subjects: 0
Study 20140405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment of illness perceptions
Number of subjects: 0
Study 20140405 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17922666 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF antagonists
Number of subjects: 0
Study 15699801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior fusion with instrumentation
Number of subjects: 43
Study 15699801 — intervention group
Group type: COMPARATOR
Intervention: Posterior spine fusion
Number of subjects: 43
Study 11936912 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/day for 3 days; n = 133)
Number of subjects: 265
Study 11936912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 132)
Number of subjects: 265
Study 10325453 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg donepezil
Number of subjects: 818
Study 10325453 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg donepezil
Number of subjects: 818
Study 10325453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 8545142 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine (mean daily dose: 273 ± 78 mg, range: 200-400 mg)
Number of subjects: 46
Study 8545142 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine
Number of subjects: 46
Study 1426661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribomunyl treatment (4 days) with amoxicillin
Number of subjects: 17
Study 1426661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6362416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine plus magnesium sulfate
Number of subjects: 41
Study 6362416 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine alone
Number of subjects: 41
Study 31198455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at PC6 and REN12 points
Number of subjects: 60
Study 31198455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 30531133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib/lenalidomide/dexamethasone (IRd)
Number of subjects: 41
Study 30531133 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Rd
Number of subjects: 41
Study 27312745 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal bed rest (BR)
Number of subjects: 32
Study 27312745 — intervention group
Group type: COMPARATOR
Intervention: Seated position (SP)
Number of subjects: 32
Study 24955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 59
Study 24955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 59
Study 24955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 59
Study 22688670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 40
Study 22688670 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 40
Study 20560941 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 3005
Study 20560941 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol
Number of subjects: 3005
Study 20560941 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration
Number of subjects: 3005
Study 20560941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration
Number of subjects: 3005
Study 20560941 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal and sublingual routes
Number of subjects: 3005
Study 18633051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular midazolam 50 mug/kg
Number of subjects: 60
Study 18633051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular midazolam 75 mug/kg
Number of subjects: 60
Study 18633051 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 60
Study 16111487 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone invitation
Number of subjects: 235
Study 12098721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 500 IU daily for four years
Number of subjects: 1193
Study 12098721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study 10084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 60 minutes
Number of subjects: 30
Study 10084439 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation for 60 minutes
Number of subjects: 30
Study 8926604 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy trials
Number of subjects: 0
Study 8926604 — intervention group
Group type: COMPARATOR
Intervention: Drug trials
Number of subjects: 0
Study 2391627 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida Probe
Number of subjects: 10
Study 2391627 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Probe
Number of subjects: 10
Study 2391627 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida Disk Probe (double passes)
Number of subjects: 10
Study 2391627 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida Disk Probe (single passes)
Number of subjects: 10
Study 2391627 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Probe (single passes)
Number of subjects: 10
Study 2391627 — intervention group
Group type: COMPARATOR
Intervention: All instruments
Number of subjects: 10
Study 7036275 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 protocol (12 patients)
Number of subjects: 23
Study 7036275 — intervention group
Group type: EXPERIMENTAL
Intervention: E76 protocol (11 patients)
Number of subjects: 23
Study 7036275 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (60 Gy)
Number of subjects: 23
Study 30508516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 52
Study 30508516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (A+R)
Number of subjects: 52
Study 30508516 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 30251369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d (n=1,467)
Number of subjects: 2867
Study 30251369 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=1,400)
Number of subjects: 2867
Study 27310331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant (QAW039)
Number of subjects: 0
Study 27310331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical CMV detection during pregnancy
Number of subjects: 147
Study 24192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal breast milk CMV levels
Number of subjects: 147
Study 24192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CD4 < 450 cells/mm(3)
Number of subjects: 147
Study 24192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Each log10 increase in breast milk CMV
Number of subjects: 147
Study 24192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk CMV level required for 50% probability of CMV transmission
Number of subjects: 147
Study 23326213 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein lycosome formulation (WPL)
Number of subjects: 40
Study 23326213 — intervention group
Group type: COMPARATOR
Intervention: Control groups (lycopene, WP singular formulation, placebo)
Number of subjects: 40
Study 19385712 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20-60 mg/day orally, once or twice daily (up to 120 mg/day)
Number of subjects: 594
Study 19385712 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 594
Study 17582663 — intervention group
Group type: EXPERIMENTAL
Intervention: Running footwear
Number of subjects: 20
Study 17582663 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf orthopaedic footwear
Number of subjects: 20
Study 17582663 — intervention group
Group type: COMPARATOR
Intervention: Control footwear
Number of subjects: 20
Study 15310635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IT lidocaine (15 mg) and sufentanil (10 microg)
Number of subjects: 49
Study 15310635 — intervention group
Group type: COMPARATOR
Intervention: IT lidocaine (50 mg)
Number of subjects: 49
Study 11782985 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 11782985 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 9638713 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral Gold oxygenator
Number of subjects: 26
Study 9638713 — intervention group
Group type: COMPARATOR
Intervention: Univox Gold oxygenator
Number of subjects: 26
Study 8208894 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 microgram/kg)
Number of subjects: 18
Study 8208894 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 2913776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 27
Study 2913776 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 27
Study 2913776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin + Hydrochlorothiazide
Number of subjects: 27
Study 2913776 — intervention group
Group type: COMPARATOR
Intervention: Atenolol + Hydrochlorothiazide
Number of subjects: 27
Study 30449812 — intervention group
Group type: EXPERIMENTAL
Intervention: rTM alone
Number of subjects: 56
Study 30449812 — intervention group
Group type: COMPARATOR
Intervention: rTM+AT
Number of subjects: 56
Study 29214616 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 grams OptiMSM methylsulfonylmethane
Number of subjects: 180
Study 29214616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 25268878 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (500 mg TID per oral)
Number of subjects: 89
Study 25268878 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 89
Study 25268878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 23778938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intanza/IDflu (9 µg for 18-59 y, 15 µg for ≥ 60 y)
Number of subjects: 240
Study 23778938 — intervention group
Group type: COMPARATOR
Intervention: Trivalent intramuscular vaccine (Vaxigrip(®) 15 µg)
Number of subjects: 240
Study 20722532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-bristled toothbrushes
Number of subjects: 120
Study 20722532 — intervention group
Group type: COMPARATOR
Intervention: Soft-bristled toothbrushes
Number of subjects: 120
Study 20722532 — intervention group
Group type: COMPARATOR
Intervention: Medium-bristled toothbrushes
Number of subjects: 120
Study 19336629 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in addition to fixed appliance therapy
Number of subjects: 19
Study 19336629 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances only
Number of subjects: 19
Study 16850439 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV) at 12 cmH(2)O
Number of subjects: 15
Study 16850439 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV) at 14 cmH(2)O
Number of subjects: 15
Study 16850439 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) at 5 cmH(2)O
Number of subjects: 15
Study 15175203 — intervention group
Group type: EXPERIMENTAL
Intervention: HEADSS chart stamp intervention during a four-week phase
Number of subjects: 306
Study 15175203 — intervention group
Group type: COMPARATOR
Intervention: Control phase with no chart stamp during a six-week phase
Number of subjects: 306
Study 10917181 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline-epinephrine (HSE)
Number of subjects: 126
Study 10917181 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl (N-butyl-2-cyanoacrylate)
Number of subjects: 126
Study 9247755 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor-based treatment
Number of subjects: 6000
Study 9247755 — intervention group
Group type: COMPARATOR
Intervention: Diuretic-based treatment
Number of subjects: 6000
Study 8100928 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rhDNase twice daily for 10 days
Number of subjects: 71
Study 8100928 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 71
Study 3493794 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1
Number of subjects: 2
Study 3493794 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone 2 mg kg‐1
Number of subjects: 2
Study 3493794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 2
Study 28606702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnuts with skin (HZN+S)
Number of subjects: 66
Study 28606702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnuts without skin (HZN-S)
Number of subjects: 66
Study 28606702 — intervention group
Group type: COMPARATOR
Intervention: Dietary advices for hyperlipidemia only (Control)
Number of subjects: 66
Study 28606702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnuts (HZN)
Number of subjects: 66
Study 27574999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation during delayed cord clamping (V‐DCC)
Number of subjects: 230
Study 27574999 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping alone (DCC only)
Number of subjects: 230
Study 24597465 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg TG hydrochloride
Number of subjects: 24
Study 24597465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg TG hydrochloride
Number of subjects: 24
Study 24597465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg TG hydrochloride
Number of subjects: 24
Study 24597465 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg TG hydrochloride (multiple doses every 12h for 5 days)
Number of subjects: 24
Study 23139970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless drainage (Group B)
Number of subjects: 54
Study 23139970 — intervention group
Group type: COMPARATOR
Intervention: Conventional large-bore nephrostomy tube drainage (Group A)
Number of subjects: 54
Study 21092220 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 193
Study 21092220 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (AA)
Number of subjects: 193
Study 18956276 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (initially 25 microg, followed by 50 microg and 100 microg every 4 hours)
Number of subjects: 224
Study 18956276 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone (3 mg every 6 hours)
Number of subjects: 224
Study 15654934 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 27.9±20.1 weeks
Number of subjects: 113
Study 12892550 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit of clinical charts with evaluation of clinical severity and adherence to explicit criteria of quality of inpatient care in OCFA.
Number of subjects: 90
Study 12892550 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care scale score.
Number of subjects: 90
Study 12892550 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 90